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ABSTRACT-
Latest evaluation and validation of cancer 
drugs and their targets has demonstrated the 
lack  and  inadequate  development  of  new 
and  better  drugs,  based  on  available 
protocols.  Even  though  the  specificity  of 
drug  targets  is  a  great  challenge  in  the 
pharmaco-proteomics  field  of  cancer 
biology,  for  eradicating  such hurdles  and 
paving the way for the drugs of future, a 
novel step has been envisaged here to study 
the  relation  between drug  target  network 
and the corresponding drug network using 
the  advanced concepts  of  proteomics  and 
network biology. The literature mining was 
done for the collection of receptors and the 
ligands.  About  1000  natural  compounds 
were  collected  and  out  of  those  300 
molecules  showed  anti-cancer  activity 
against  colon cancer. Ligand Vs multiple 
receptor  docking  was  done  using  the 
software Quantum 3.3.0;  the results  were 
further  used  for  the  designing  of  a  well 
connected Protein Ligand Interaction(PLI) 
network  of  colon  cancer. The  obtained 
network is then extrapolated to sort out the 
receptors expressed in the specific cancer 
type.  The  network  is  then  statistically 
analyzed and represented by the graphical 
interpretation, in order to ascertain the hub 
nodes and their locally parsed neighbours. 
Based  on  the  best  docking  scores,  the 
graphs obtained from the docking analysis 
are  statistically validated with the help of 
VisANT.  In the network three hub nodes 
Neutrophil  cytosol  factor  2,  UV excision 
repair  protein  RAD23  homolog  A,  & 
Receptor-type tyrosine-protein phosphatase 
eta were  identified,  which  showed  the 
highest  interaction  with  the  ligands. 
Butyrate  and  Farnesol showed  highest 
interaction  as  ligands.  Multiple  Sequence 
Alignment  was  done  of  the  binding  site 
sequence of the drug targets to find out the 
evolutionary closeness of the binding sites. 
The phylogenetic tree was also constructed 
to further validate the observation. Further 
in-vitro  and  in-vivo  studies  needs  to  be 
done to analyse the receptor specificity and 
anti tumor activity of these compounds in 
Colon cancer.
Keywords: Signal transduction modulators, 
Colon Cancer, Hub Nodes, Natural 
Ligands, PLI (Protein Ligand Interaction)
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Introduction to Study
Treatment of diseases and the application 
of  scientific  approach  in  the  field  of 
computer  aided  drug  discovery  and 
designing  has  become  much  more 
pronounced with the increased occurrences 
of genetic diseases in the recent past. Hence 
there is a lot of work that needs to be done 
in the field of in-silico drug designing in 
order to get rid of such new diseases using 
Network Pharmacology. The two methods 
by which a drug does its role is by either 
stimulating the target activity(agonist) or by 
down  regulating   its  activity(antagonist) 
[1].  In  this  paper  we  have  discussed  an 
integrated  approach   of  simultaneously 
focussing on  Drug-Drug Target with Drug 
Target-Cancer protein interactions, that has 
the additional capability to act on cancerous 
proteins which are generally out of reach in 
normal  circumstances   in  the  classical 
analysis  protocols,  and  also   provides  a 
model  for  the  molecular  mechanisms 
involved in the target prediction[2].
Cancer  is  a  term  used  for  describing 
uncontrolled  and  abnormal  cells  division 
along  with  the  ability  to  invade  other 
tissues.  Cancer  can  be  classified  into 
various  categories  depending  on  its  form 
and the cell  type  it  is  involved with  [3]. 
Colon or  Colorectal  cancer  is  one  of  the 
most common cancers in the world and is 
one of the leading causes of cancer related 
deaths around the world. The development 
of Colon cancer begins with the    abnormal 
cell growth & faulty repair  mechanism in 
the  colon  cell  lining  and  such  cells  are 
known  as  Polyps.  Polyps  are  generally 
benign  but  do  have  the  potential  to  turn 
cancerous. Like  any  other  cancer  type, 
Colon cancer is initiated by a signal to the 
receptor,  loss  of  function of  intermediary 
genes and hence resulting in erroneous cell 
behaviour and function [4].
Oncogenic  proteins  that  participate  in 
signal transduction pathways play a pivotal 
role in the transmission of a signal from the 
extracellular environment, through the cell 
membrane,  into the cytoplasm and to  the 
nucleus where transcription is initiated and 
even  modulated  to  generate  proteins  that 
will eventually contribute to the cancerous 
phenotype. The function of these proteins is 
vital  for  homeostasis  in  the  cells  and 
tissues,  moreover  they  control  processes 
such  as  cell  division,  differentiation  and 
apoptosis. All these molecules are potential 
targets for anti cancer drug designing due 
to the very fact that inhibition or activation 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
70
9.
1 
: P
os
te
d 
27
 J
ul
 2
01
0
of their function will lead to the elimination 
of the tumor cells. Issues related to these 
compounds,  such  as  mechanism-based 
toxicity  and  development  of  resistance, 
have  to  be  addressed  in  order  to  ensure 
their  successful  development  as  chemo 
preventive  agents.  The  continuation  of  the 
research  in  the  development  of  these 
compounds as drugs for the future cancer will 
pave  the  way  for  adoption  of  novel 
strategies[5], [6].
Treatment of cancer involves a very high 
degree of complications and unseen factors 
like the possible side-effects, hence making 
successful treatment of cancer all the more 
difficult. Most cancers are highly invasive 
and there are problems of recurrence even 
after  surgery,  chemotherapy and radiation 
treatment. Butyrate  is  found  to  play  a 
protective role in colon cancer by inhibiting 
the enzymes up regulated in colon cancer 
and  responsible  for  the  classic  erroneous 
growth [7].The  iso-prenoid  alcohol 
Farnesol  is  an  effective  inducer  of  cell 
cycle arrest  and apoptosis in a  variety of 
carcinoma cell types. In addition, Farnesol 
has  been  found  to  function  as  a  chemo 
preventative and anti-tumor agent in colon 
cancer [8]. 
Gene  expression  is  the  result  of  post 
transcriptional & translational modification 
of  gene  products.  Therefore  the  up-
regulated  genes  (highly  expressed)  in 
Colon cancer are sorted out for the further 
validation by experimentation and analysis 
by  Hyper  Geometric  Test.  The  result 
obtained is fed into a well defined network, 
demonstrating the relationship between the 
various  involved  elements  in  order  to 
ascertain  their  biological  properties  and 
functions. The centralities of the biological 
entities  define  their  importance  and 
biological hierarchy in the devised network.
 
Figure 1: Overall work flow in the designing of   a network.
Materials and Methods
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A. Data mining, Target & 
Lead Identification:
The first step involved was the collection of 
Protein  Drug  Targets.  From  the  PDB 
database,  the  disease  proteins  were 
collected  in  order  to  study  the  Colon 
cancer.  The Colon cancer specific natural 
Signal  Transduction  Modulators  were 
annotated from a wide range of publishers 
and  databases  like  Wiley,  Blackwell 
Synergy,  Medline,  Pubchem,  Ingenta 
Connect, Chemfinder, Drug Bank, etc. The 
protein  structures  were  collected  from 
various online databases. The structures of 
the  compounds i.e.  the  ligands were  also 
collected from various sources.
Collection of Drug Targets
The colon cancer related proteins, extracted 
and validated leading to the 3 drug targets 
were considered based on their association 
with  the  specific  cancer  and  the 
significance  level  of  the  protein  in  the 
disease as well as its involvement with the 
cellular processes, biological functions and 
molecular functions were assessed.
     
Table  1:  Ligand  Drug  Target  Interaction 
Scoring Matrix.
In  Table  1  The  Ligand-  Drug  Target 
Interaction between the 3 drug targets and 
the screened off 2 ligands (from about 300 
ligands)  is  depicted.  The  possible 
interaction between the drug targets and the 
ligands is the building block of our study to 
obtain  the  best  signal  transduction 
modulators. The modulators have had been 
screened  of  based  on  the  docking  scores 
and only the best ones have made through 
into our study. Such method of screening is 
based on the fact that the signal modulators 
with  higher  scores  are  supposed  to  give 
greater interactions and the drugs based on 
this concept should give out better result.
In order to study the effects of colon cancer 
specific signal transduction modulators on 
the  biological  network  of  colon  cancer, 
ligand  Vs  multi  receptor  docking  was 
performed  to  elucidate  the  high  grade 
specificity of the ligands for best fit. The 
analysis has been done on the basis of their 
docking  score  and  RMS value.  After  the 
protein  and  ligand  docking,  the  scores 
matrix  was  created  from  the  scores 
obtained.  Therefore  a  Structural  Biology 
approach  has  been  used  for  the 
classification  and  interpretation  of  the 
Systems Biology Network Model. 
DT1* DT2* DT3*
LD1* 65.97 58.94 NA
LD2* NA NA 82.13
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Table 2: Protein Protein Interaction Scoring 
Matrix.  The  cancer  proteins  are  plotted 
against the number of protein interactions 
that they are having and hence the Protein 
Protein  Interaction  Scoring  Matrix  was 
obtained.  The scoring matrix so obtained, 
verifies  the  fact  that  indeed  the   signal 
transduction modulators having the highest 
docking scores have the highest interactions 
and hence provide an insight into the fact 
that the drugs conceptualised on this basis 
have better chances against the other drugs 
to  carry  out  the  signal  modulation 
procedure, finally resulting in the state of 
homeostasis in the target drug targets.
B. Statistical Analysis:
The  two  sets  (X,  Y)  of  ligands  and  the 
target  receptors  respectively  are  taken, 
using their mean docking score & by help 
of the tool, VisANT [9] the highest degree 
of  interaction  was  found  to  be  with 
Neutrophil  cytosol  factor  2,  UV excision 
repair  protein  RAD23  homolog A, 
Receptor-type tyrosine-protein phosphatase 
eta genes,  where  they  shared   degree 
distribution and it was found to be average 
score  of  3.938  and  the  correlation 
coefficient was found to be 0.95, the graph 
was plotted for this statistical analysis data. 
Node degree is  represented by its  visible 
interactions.  The distribution is  calculated 
to see their  fitness with power-law curve. 
The highest interacting proteins were found 
to be
Neutrophil  cytosol  factor  2,  UV excision 
repair  protein  RAD23  homolog  A, 
Receptor-type tyrosine-protein phosphatase 
eta [10].
*P.I= number of protein interactions.
*LD=ligands(signal  transduction 
modulators)
*DT= drug targets
Figure  2:  Highest  Hub  nodes  show 
interaction with compounds
Figure 3: Degree distribution calculation
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Figure  4:  Protein  –Protein  interaction 
network
Fig  4:  Shows  the  Drug  Target  Protein- 
Cancer Protein interaction. In this network 
Receptor-type tyrosine-protein phosphatase 
eta  is the hub node. Many proteins related 
to  the Receptor-type  tyrosine-protein 
phosphatase eta and other targets show very 
weak  interaction  to  the  Drug  Target 
Proteins which shares degree of 1.783, and 
the correlation coefficient was found to be 
1.0.The graph distribution was found to be 
the average score & it was plotted for the 
statistical analysis data.
In this network Neutrophil cytosol factor 2, 
UV  excision  repair  protein  RAD23 
homolog A,  Receptor-type tyrosine-protein 
phosphatase eta  are the proteins related to 
colon cancer.   The scoring matrix  of  the 
Drug  target  Protein-Cancer  Protein 
Interaction was done with the aid of PIPS: 
Human  Protein  Protein  Interaction 
Prediction  Server 
(http://www.compbio.dundee.ac.uk/www-pips/). 
PIPs  is  a  database  of  predicted  human 
protein-protein  interactions.  The 
predictions have been made using a naïve 
Bayesian classifier  to calculate a  score of 
interaction.  There  are  37606  interactions 
with  a  Score  1  indicating  that  the≥  
interaction is more likely to occur than not 
to occur.
Figure 5: Graph between the drug targets 
and number of interactions.
In  Fig  5  Blue  line  indicates  the  Protein-
Protein Interactions  scores  graph between 
drug targets & cancer proteins found from 
the  PIPs  database.  The  peaks  are 
represented  by  dots.  2NZ6  shows  the 
highest interaction score. 
C.  Sequence  and 
Evolutionary Analysis:
The  identification  of  a  good binding  site 
and characterization of a drug target protein 
is of prime importance that leads it into its 
functional  annotations.  Therefore  multiple 
sequence alignment is done to measure the 
evolutionary  conservation  of  the  binding 
sites  of  drug  proteins  that  hold  much 
evidence for the best fit  of  a ligand. The 
conserved  binding  site  proved  to  be 
functionally  enriched.  The  sequence 
analysis of the binding site was done for the 
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Signal transduction Drug Target  Proteins- 
Neutrophil  cytosol  factor  2, UV excision 
repair  protein  RAD23  homolog  A   and 
Receptor-type tyrosine-protein phosphatase 
eta.  The sequence analysis  score shows a 
high  degree  of  evolutionary  conservation 
among  the  binding  site  sequences  of  the 
drug  target  proteins.  The  phylogenetic 
profile  of  the  proteins  depicts  low 
substitution rate & less gap penalty which 
indicates that they belong to same protein 
family.  The  evolutionary  tree  was  drawn 
using  CLUSTALW2  [11].  A  rooted 
Phylogenetic  tree  with  a  unique  node 
corresponding to the most recent common 
ancestor was found using the evolutionary 
analysis study.
Figure  6:  Clustalw2  result  showing  the 
similarity  in  the  Drug  Target  Gene 
Sequence
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
70
9.
1 
: P
os
te
d 
27
 J
ul
 2
01
0
Figure  7: Target  sequences  show 
evolutionary relationship
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Figure 8: The relation between ligand and Drug Target Proteins. Small molecules i.e. the 
Signal Transductional modulators interact with their disease protein targets to generate a 
work flow, in which a drug and a protein are connected to each other through the medium 
of target proteins. As some of the small molecules cannot directly interact with the desired 
target due to their small size, they do require some other proteins that help them become fit 
to act upon the target proteins.
D. Matrix Analysis
The scoring matrix was plotted using the scores obtained from multiple receptor docking to 
identify the possible drug targets and were found to be  Neutrophil cytosol factor 2,  UV 
excision repair protein RAD23 homolog A, & Receptor-type tyrosine-protein phosphatase 
eta[Table no-1].
To obtain the best signal transduction modulators, the number of interactions obtained 
from the protein protein interactions were drawn in a scoring matrix to further validate the 
fact that the signal transduction modulators indeed have greater interactions and hence 
have better chances of serving the purpose as drugs for colon cancer[Table-2]. 
Results-
Thus, out of 300 natural molecules two molecules were selected for final study namely 
Butyrate and Farnesol that displayed the highest ligand and Drug Target Interactions with 
the obtained hub node proteins of the specific cancer.  Both of the signal transduction 
modulators were filtered out from the available compounds, first by scores obtained from 
the multiple receptor docking and then by number of protein protein interactions. The 
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signal transduction modulators obtained from the screening procedure performed better 
than the other molecules. For the effective targeting and signal modulation of the involved 
target receptor sites multiple sequence alignment was performed to obtain the sequence 
conserved in evolution. The signal transduction modulators that efficiently and effectively 
target the conserved sequences can neutralize the abrupt signals and can bring the cell, 
back into the normal homeostatic condition.
Conclusion-
The  interpretation  of  colon  cancer  network  gives  3  hub  nodes.  The  most  prominent 
interactions were observed with  Neutrophil cytosol factor 2, UV excision repair protein 
RAD23  homolog  A &  Receptor-type  tyrosine-protein  phosphatase. The  compounds 
namely  Butyrate  and  Farnesol  exhibited  the  highest  interaction  with  the  up-regulated 
proteins in colon cancer. The phylo-genetic tree obtained also showed the  evolutionary 
closeness of the binding sites  in the Drug Target Proteins that  has been conserved in 
evolution process. The significance of the work is to validate the target specificity of the 
naturally occurring anti oxidant drugs. Most of the drugs failed to work properly due to the 
lack of proper target identification. But here we have taken a predictive measure to map the 
natural oxidants to the colon cancer specific disease network so that an organized data can 
be available on the drug targets involved in the colon cancer and even their anti- oxidants 
agents. This study will further contribute to the biomedical field to develop new drugs with 
best targets.
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